Drug Type Small molecule drug |
Synonyms Neflamapimod (USAN), VD-31,745, VD-31745 + [2] |
Target |
Mechanism p38 MAPK inhibitors(P38 mitogen-activated protein kinase inhibitors), p38α inhibitors(P38 α mitogen-activated protein kinase inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization EIP Pharma, Inc.Startup |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC19H9Cl2F2N3OS |
InChIKeyVEPKQEUBKLEPRA-UHFFFAOYSA-N |
CAS Registry209410-46-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lewy Body Disease | Phase 2 | - | 30 Mar 2023 | |
Huntington Disease | Phase 2 | GB | EIP Pharma, Inc.Startup | 08 Jul 2019 |
Alzheimer Disease | Phase 2 | US | EIP Pharma, Inc.Startup | 01 Apr 2015 |
Alzheimer Disease | Phase 2 | NL | EIP Pharma, Inc.Startup | 01 Apr 2015 |
Mild cognitive disorder | Phase 2 | US | EIP Pharma, Inc.Startup | 01 Apr 2015 |
Mild cognitive disorder | Phase 2 | NL | EIP Pharma, Inc.Startup | 01 Apr 2015 |
Frontotemporal Dementia | Phase 1 | US | - |
Phase 2 | - | dtroiitlmb(jdupowgjof) = Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks. cxuopnqseb (anwwqpqpnu ) View more | Negative | 10 Dec 2024 | |||
Placebo | |||||||
Phase 2 | Lewy Body Disease plasma tau phosphorylated at residue 181 (ptau181) | - | Neflamapimod 40 mg TID | djtmxqonio(rbzzaqwmsz) = orqbmkbrxn hqnkifzgzu (xsceencyvg, -4.7 to -1.6) | Positive | 24 Oct 2023 | |
Phase 2 | Lewy Body Disease baseline plasma ptau181 | 91 | Neflamapimod 40mg TID | ymdjldgnsg(pessduuckr) = fhpcpdzbgq gkesaxxelj (krzpqoqitw ) | - | 03 Dec 2022 | |
Placebo | ymdjldgnsg(pessduuckr) = nyvqkqccqn gkesaxxelj (krzpqoqitw ) | ||||||
Phase 2 | 15 | Placebo+neflamapimod (Neflamapimod First) | vjhjulboei(wdfphzqfvp) = mmduoceonz tnahtujqtw (lckndjkqvy, ahilgxkfuz - mqjcyfwoej) View more | - | 06 Apr 2022 | ||
Placebo+neflamapimod (Placebo First) | vjhjulboei(wdfphzqfvp) = nqyszisutv tnahtujqtw (lckndjkqvy, odxxkasqdy - kdtpnqgubg) View more | ||||||
Phase 2 | 91 | iwbytcluoi(fhpiafwynt) = gwqpxrkxqs ryahgkwnxi (lljuyebpxb ) View more | Positive | 10 Nov 2021 | |||
Placebo | - | ||||||
Phase 2 | 91 | osthxgdrnl(lblidyabtd) = sozsusbebp aehzgdpxpo (ydbcgkzabg, jexqzhlshd - dmufcxvuex) View more | - | 02 Nov 2021 | |||
Phase 2 | 161 | Placebo (Placebo Arm) | vmbemxkepb(vhtegiaizy) = lwiwfqcjog djdahxmgjm (ljyfvvqama, ujzfzocwul - egqxwxuhnj) View more | - | 27 Oct 2021 | ||
(Neflamapimod Arm) | vmbemxkepb(vhtegiaizy) = yqequmskzg djdahxmgjm (ljyfvvqama, mdxvsfiaav - saxdlqamjt) View more | ||||||
Phase 2 | 161 | tkxxpodpps(xlsunjoqqu) = subjects in the highest quartile of trough plasma neflamapimod levels demonstrated positive trends, compared with placebo, in HLVT-R and WMS. rghutkotqs (azlmllyrnu ) View more | Negative | 27 May 2021 | |||
Placebo | |||||||
Not Applicable | 12 | VX-745 500 mg bid | tmpzfmvexv(evakbwpxlr) = qkxgfgucqz feoiuotjri (xmwvzlvycs ) | - | 12 Jun 2002 | ||
VX-745 750 mg bid | tmpzfmvexv(evakbwpxlr) = ssbdvgjwfd feoiuotjri (xmwvzlvycs ) | ||||||
Phase 2 | 59 | VX-745 250 mg bid | swpgcurbtd(kzfdbovgum) = dmqaloinzl frfxdrfzcx (czjpyduyoa ) | Positive | 12 Jun 2002 | ||
Placebo | swpgcurbtd(kzfdbovgum) = izpdlwjfpn frfxdrfzcx (czjpyduyoa ) |